A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/517 (2006.01) A61K 9/12 (2006.01) A61K 9/72 (2006.01)
Patent
CA 2536053
The invention relates to a powder inhalant for pulmonary or nasal inhalation, comprising the CGRP antagonist 1-[N?2¿-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine (A) in the form of spherical, nano-structured microparticles, which are stable in the amorphous state under normal conditions (T < 50 ·C, relative humidity < 75%), a method for production of said microparticles and the use thereof for the production of the powder inhalant for the treatment of headaches, migraines and cluster headaches.
La présente invention concerne une substance à inhaler pulvérulente pour l'inhalation pulmonaire ou nasale qui contient l'antagoniste CGRP 1[<I>N</I>?2¿-[3,5-dibromo-<I>N</I>-[[4-(3,4-dihydro-2(1<I>H</I>)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-pipérazine (A) sous forme de microparticules sphériques nanostructurées qui sont stables à l'état amorphe dans des conditions normales (T < 50 ·C, humidité relative < 75%). La présente invention concerne également un procédé de production de ces microparticules ainsi que leur utilisation pour fabriquer ladite substance pulvérulente destinée à traiter les céphalées, la migraine et l'algie vasculaire de la face.
Schmelzer Christel
Trunk Michael
Weiler Claudius
Boehringer Ingelheim International Gmbh
Fetherstonhaugh & Co.
LandOfFree
Powder formulation comprising the cgrp antagonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Powder formulation comprising the cgrp antagonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Powder formulation comprising the cgrp antagonist... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1890296